Sphingosine-1-phosphate (S1P), a lipid signaling molecule produced by endothelial cells, 3 is required for development and homeostasis of blood vessels. However, its role during 4 lymphatic vessel development is unclear. We show in murine newborns that pharmaco-5 logically enhanced S1P signaling increases VEGF-A-dependent LEC proliferation. In con-6 trast, S1PR1 inhibition, mediated by the antagonist NIBR0213 or LEC-specific genetic 7 deletion of S1pr1, promotes filopodia formation and vessel branching, independent of 8 VEGF-A. To investigate the S1P and VEGF-A signaling crosstalk observed in vivo, we 9 used LECs cultured in vitro. We demonstrate that S1P activates endogenous S1PR1 in 10
Measurements of S1P concentration 13 S1P concentrations were measured as previously described (Billich et al., 2013) . To re-14 duce unspecific binding, extracts were subjected to acetylation as described 15 in (Berdyshev et al., 2005) . Sphingosine derivatives were detected in positive mode; neg-16 ative ionization was used for S1P. Quantification was performed based on the area ratios 17 of the compound over internal standard in the extracted ion chromatograms. Recovery 18 was >86% for all analytes. The limit of quantification, as determined by the lowest cali-19 bration sample showing signal-to-noise ratio >5 and accuracy <14%, was 0.5 ng/ml for 20 Sph, 0.1 ng/ml for S1P.
22
Electric Cell-substrate Impedance Sensing (ECIS) 1 The lymphatic endothelial cell barrier tightness was assessed using an ECIS® ZΘ instru-2 ment with a 16-well array station (Applied Biophysics). 8-well chamber slides (8W10E+, 3 ibidi) were pre-incubated with 50 µg/ml fibronectin (Roche) and then washed with sterile 4 H2O. Next, 30000 adult human dermal LECs per well were plated in EGM and impedance 5 values were recorded at 4,000 Hz every 30 seconds. When a monolayer with stable im-6 pedance levels of 3000-3500 ohm was formed, treatments with compounds started. To 7 investigate LEC endogenous S1P functions, 10 M SKI-II or DMSO control was spiked 8 into corresponding wells. After 4 h cells were washed with PBS and starved in EBM con-9 taining again 10 M SKI-II for 3 h. Next, cells were treated ± 1 μM S1P, S1P+0.3 μM 10 NIBR0213 or DMSO control. To rule out NIBR0213 toxic effects, 0.1 or 0.01 μM 11 NIBR0213 was spiked into corresponding wells. After 5 h 10 μM S1P or DMSO control 12 were spiked into corresponding wells. Graphs were generated using TIBCO Spotfire 13 6.5.3. Impedance curves were normalized to DMSO control. 14 15 Immunofluorescent approaches for in vitro experiments 16 Cells were starved for 4 h or overnight in medium without FCS and received indicated 17 treatments for indicated times. Then cells were fixed with 4% PFA for 10 min at room 18 temperature and washed with PBS before blocking for 1 h in immunomix (PBS containing 19 5 % donkey serum, 1 % bovine serum albumin (BSA) and 0.1 % Triton-X). The following 20 antibodies were incubated overnight at 4°C: rat anti-human CD31 (DAKO, M082329-2), 21 rabbit anti-human S1PR1 (Santa Cruz, sc-25489), goat anti-human VEGFR-2 (R&D sys-22 tems, AF357), rabbit anti-human Rab5 (Cell Signaling, #3547P). After an intense wash 23 step in 0.1% Triton-X PBS, samples were incubated for 1 h at room temperature with 1 Alexa Fluor 488, 594 or 647 nm-conjugated secondary antibodies (Invitrogen). Samples 2 were imaged with a Zeiss LSM 700 (Zeiss) confocal microscope using the Zen 2011 SP3 3 (black edition) software or for VEGFR-2 trafficking with a Yokogawa CV7000 system us-4 ing the CellVoyager R1.17.05 software. Yokogawa images were analyzed with ImageJ:
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The perinuclear area was defined by Hoechst area plus a 1.625 m radius and total cell 6 area was defined based on CD31 plasma membrane staining. Total cell VEGFR-2 was 7 defined as 100%. Values were normalized to DMSO control. Homogeneous time resolved fluorescence (HTRF) 10 HTRF approaches (Cisbio) were used to determine VEGFR-2 pTyr1175 and ERK 11 pThr202/Tyr204 levels. To measure VEGFR-2 pTyr1175 levels after VEGF-A stimulation 12 with or without S1PR1 pathway modulation, 40000 cells per 96 well were seeded in EGM 13 in the morning. In the evening, cells were washed with PBS and starved overnight in EBM 14 without FCS. Next, cells were stimulated with the indicated treatments for 2 and 5 min 15 and 2 h before processing according to manufacturer's instructions. For determination of 16 pERK1/2 levels in the presence or absence of SKI-II, 20000 human dermal LECs per 96 17 well were seeded in EGM. The next day 10 M SKI-II was spiked into corresponding wells 18 and incubated for 4 h before EGM removal, a PBS wash and the addition of EBM starva-19 tion medium without FCS ± 10 M SKI-II. Cells were starved for 3 h before 10 min stimu-20 lation with the indicated treatments. Next, cells were processed according to manufac-21 turer's instructions. Fluorescent signals were measured with TRF Light Unit EnVision 22 (PerkinElmer). EC50 and Emax were calculated with Prism 6 (GraphPad Software).
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Cell proliferation assay 1 For the 5-ethynyl-2´-deoxyuridine (EdU) proliferation assay, 5000 LEC per well of a 96 2 well plate were seeded in EGM in the morning. In the evening, cells were washed with 3 PBS before an overnight starvation in EBM. The next morning, cells were treated with 4 100 ng/ml VEGF-A ± 0.3 M NIBR0213 or DMSO control and in the evening 10 M EdU 5 was spiked. 24 h after the addition of VEGF-A cells were fixed with 4 % PFA before further 6 processing according to the Click-iT EdU Imaging Kit (Invitrogen (70/30%) or PBS/PEG200/5% glucose (50%/35%/15%) for co-treatments, 3 or 6 20 mg/kg/day VEGF-A neutralizing antibody 4G3 (Novartis) diluted in PBS/PEG200/5% glu-21 cose (50%/35%/15%), 1, 5 or 10 mg/kg/day NIBR0213 (Novartis) diluted in PEG200/5% 22 glucose (70/30%) or PBS/PEG200/5% glucose (50%/35%/15%) for co-treatments with 23 4G3 (6 mg/kg/day) from postnatal day (P) 0.5 to P3.5 and were sacrificed at P4.5. To 1 induce recombination events, homozygous S1pr1 flx and Prox-1-CreERT2+ (S1PR1-2 iΔLEC) or Prox-1-CreERT2-(control) littermates received intragastric injections of 50 g 3 tamoxifen (Sigma), dissolved in EtOH and sunflower seed oil (Sigma) from P1 to P4.
4
Tissues were harvested at P7 to allow enough time for recombination to occur. Abdominal skin or diaphragms were harvested and skin samples were incubated for 1 h 12 in 20 mM EDTA at 37°C to facilitate the removal of the epidermis. Then tissues were fixed 13 for 2 h in freshly prepared 4% PFA at 4°C. Next, samples were washed in PBS and 14 blocked in immunomix (described above) for 1 h at RT before overnight primary antibody 15 incubation at RT. The following primary antibodies were used: rat-anti mouse S1PR1 16 (R&D Systems, MAB7089), hamster anti-mouse CD31 (Millipore, MAB1398Z), goat anti-17 mouse Prox-1 (R&D Systems, AF2727), rabbit anti-mouse LYVE1 (AngioBio, 11-034), 18 goat anti-mouse LYVE1 (R&D Systems, AF2125), rabbit anti-mouse 19 RM-9106-S1), goat anti-mouse VEGFR-2 (R&D Systems, AF644). The next day, whole 20 mounts were washed and incubated for 2 hours with AlexaFluor 488, 594 or 647-conju- To assess growth factor levels in postnatal diaphragms, tissues were collected and 13 mRNA levels were assessed by qPCR. To do so, two diaphragms of P2.5 C57Bl6 pups 14 were collected in RNA later (Qiagen) before they were processed in RLT buffer containing 15 1% mercaptoethanol (Sigma) with the help of metal beads (MP Biomedicals) and the Increasing tissue S1P levels enhances lymphatic endothelial cell proliferation in vivo in a 3
VEGF-A-dependent manner 4
To study the role of S1P in early postnatal lymphangiogenesis, we used a previously 5 established murine model where lymphatic vessels on the pleural side of the diaphrag-6 matic muscle are monitored (Ochsenbein et al., 2016) . In a first series of experiments we 7 enhanced S1P signaling by treating pups from postnatal day (P) 0.5-3.5 with Cmpd 31, a 8 highly specific S1P lyase inhibitor that increases S1P concentrations in vivo (Weiler et al., 9 2014) . At P4.5, LYVE1+ lymphatic vessels expressed S1PR1, which was also present on 10 some single cells and on CD31+ blood vessels ( Fig. 1A) . Intraperitoneal injection of 20 11 mg/kg/day of Cmpd 31 significantly increased S1P levels in muscle tissue ( Fig. S1A ) and, ) and Vegf-a is the most abundantly expressed endothelial growth factor in the post-20 natal diaphragm at P2.5 ( Fig 1F) . We therefore treated neonates from P0.5-3.5 with Cmpd Fig S1C) . Hence, we report that enhanced S1P signaling enlarges lymphatic vessel 8 diameters and boosts LEC proliferation in a VEGF-A-dependent manner in vivo, without 9 affecting vessel branching. To complement our pharmacological approach of investigating S1P signaling, we used 14 the specific S1PR1 competitive antagonist NIBR0213 (Quancard et al., 2012) during early 15 postnatal lymphangiogenesis. We treated pups from P0.5 to P3.5 i.p. with 10 mg/kg/day 16 of NIBR0213 and sacrificed them at P4.5. At this time point, all NIBR0213 -treated pups 17 had developed chylus ascites, indicative of malfunctioning lymphatic vessels (Fig 2A) .
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Interestingly, analyses of diaphragm whole mounts showed that inhibition of S1PR1 in 19 vivo only mildly reduced LEC proliferation and had no effect on LYVE1-positive lymphatic 20 vessel area, the total lymphatic vessel network expansion or the calculated lymphatic 21 vessel diameter ( Fig 2B, Fig S2A) . However, NIBR0213 led to a strong, dose-dependent 22 increase in branch formation ( Fig 2B, Fig S2B) and enhanced filopodia formation ( Fig 2B, 1 Fig S2C) , suggesting that S1PR1 activity inhibits LEC migratory, filopodia-forming re-2 sponses in vivo. Neutralization of VEGF-A did not alter NIBR0213-mediated enhanced 3 branch formation (Fig S2D, E) .
4
To demonstrate that the effects of S1PR1 antagonism are indeed intrinsic to LECs we 5 used an inducible genetic loss-of-function approach to delete S1pr1 specifically in this 6 cell type. Homozygous S1pr1 flx and Prox-1-CreERT2+ or Prox-1-CreERT2-littermates 7 were treated intragastrically from P1-4 with 50 g/day tamoxifen and diaphragms were 8 harvested at P7. Analyses of diaphragm whole mounts revealed that, compared to ho-9 mozygous S1pr1 flx and Prox-1-CreERT2-control pups, S1PR1 was strongly decreased 10 on LYVE1+ lymphatic vessels in homozygous S1pr1 flx and Prox-1-CreERT2+ (S1PR1-11 iΔLEC) littermates, while the S1PR1 expression on blood vessels remained intact ( Fig   12   S2F ). Importantly, the lymphatic endothelial cell-specific S1PR1 loss-of-function recapit-13 ulated the phenotypes caused by NIBR0213 treatment. Lymphatic vessel branching and 14 filopodia formation were strongly increased whereas no changes in lymphatic vessel di-15 ameter and LEC proliferation were found ( Fig 2C, D, Fig S2G) . Deficiency of LEC S1PR1 16 led to a decreased lymphatic network expansion, suggesting that lymphatic vessel growth 17 was inefficient ( Fig 2C) . Superficial lymphatic vasculature in the dermis likewise showed 18 increased branch formation, implying a systemic and not an organ-specific effect (Fig 2E) . 19 Thus, LEC-specific S1PR1 signaling strongly inhibits lymphatic endothelial cell filopodia 20 formation and vessel branching and is required for a balanced expansion and proper 21 function of the lymphatic vasculature during postnatal development.
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Lymphatic endothelial cells in vitro exhibit autocrine and constitutive S1P-S1PR1 signal-
To study the molecular mechanism by which S1P regulates lymphatic vessel develop-3 ment, we characterized S1P production and signaling in primary human dermal lymphatic 4 endothelial cells in vitro. Liquid chromatography-mass spectrometry analyses of LEC-5 conditioned medium showed that LECs secrete high amounts of S1P ( Fig 3A) . Treatment 6 with SKI-II, an inhibitor of sphingosine kinases 1+2 that phosphorylate sphingosine to 7 S1P, completely abolished S1P production. Of note, we showed that already plain, un-8 conditioned commercial endothelial growth medium (PromoCell EGM-MV) contains ca. 6 9 nM of S1P ( Fig 3A) and conclude that active concentration of S1P is constantly present 10 in regular LEC in vitro culture.
11
Next, we assessed whether S1P can act on LECs directly in an autocrine manner by 12 measuring endothelial barrier function, a process known to be modulated by S1P (Xiong 13 and Hla, 2014), using electric cell-substrate impedance sensing (ECIS) with high temporal 14 resolution. Inhibition of autocrine S1P production by SKI-II treatment led to the destabili-15 zation of the LEC barrier and this effect could be overcome by the addition of exogenous 16 S1P ( Fig 3B) . We then used the competitive and selective antagonist NIBR0213 and 17 showed that S1P-induced barrier stabilization was fully reversed, demonstrating the in-18 volvement of S1PR1. NIBR0213 is not toxic for LECs as excess S1P could compete for 19 S1PR1 binding and overcome NIBR0213-induced barrier opening ( Fig S3) . Thus, LECs 20 produce S1P that acts via S1PR1 in an autocrine and constitutive signaling loop that 21 manifests in LEC barrier function regulation. Furthermore, LECs expressed S1PR1 pro-1 tein that was internalized upon stimulation with a saturating concentration of 1 M exog-2 enous S1P ( Fig 3C) .
The mitogenic effect of VEGF-A on lymphatic endothelial cells in vitro depends on S1P-5 S1PR1 signaling 6 In order to gain a better mechanistic understanding of the interaction between VEGF-A 7 and S1P signaling resulting in the enlarged lymphatic vessel diameters and LEC prolifer-8 ation in vivo, we studied VEGF-A-mediated proliferation of human dermal LECs in vitro in 9 the presence or absence of S1PR1 signaling. VEGF-A at 100 ng/ml significantly in-10 creased cell proliferation as determined by EdU incorporation, and strikingly, this effect 11 was completely inhibited by NIBR0213 ( Fig 4A) . Thus, S1PR1 signaling is required for 12 VEGF-A-mediated LEC proliferation in vitro.
14
Autocrine S1P-S1PR1 signaling controls VEGF-A-induced ERK1/2 activation. 15 We went on to study growth factor-induced ERK1/2 activation in vitro, a highly relevant ). Indeed, NIBR0213 inhibited pERK1/2 activation mediated by VEGF-A and caused a 21 significant increase in EC50 of VEGF-A and strongly decreased the Emax of VEGF-A 1 down to 50% (Table 1) . Thus, we conclude that VEGF-A-induced ERK1/2 activation is 2 strongly dependent on S1PR1 signaling. Furthermore, at 10ng/ml VEGF-A, a sub-satu-3 rating concentration, the addition of exogenous S1P significantly increased growth factor-4 induced ERK1/2 activation ( Fig S4A) . Hence, S1P-S1PR1 signaling enhances and 5 S1PR1 antagonism limits VEGF-A-mediated ERK1/2 activation in LECs in vitro. 6 A positive signaling cross-talk between S1PR1 and VEGFR-2 in LECs was unexpected 7 as earlier work in HUVECs suggested a decrease of VEGF-A-induced pERK1/2 levels 8 (Gaengel et al., 2012) . We therefore carried out experiments with human umbilical vein 9 endothelial cells (HUVECs) and obtained results similar to the ones reported here for 10 LECs. Addition of exogenous S1P 1 h prior to or simultaneously with VEGF-A increased 11 pERK1/2 levels and NIBR0213 significantly reduced the signal (Fig S4B) .
12
To further confirm that growth factor-induced ERK1/2 activation depends on autocrine 13 production of S1P we assessed the pERK1/2 response after VEGF-A treatments in the 14 presence of the sphingosine kinase inhibitor SKI-II ( Fig 4C) . With SKI-II, VEGF-A was not 15 able to induce ERK1/2 activation significantly compared to control. Co-stimulation with 16 exogenous S1P overcame the SKI-II block for VEGF-A and significantly increased 17 pERK1/2 levels compared to VEGF-A alone (Fig 4C) . This increase was inhibited by 18 S1PR1 antagonism.
19
Taken together, these results show that VEGF-A-induced ERK1/2 activation strongly de-20 pends on autocrine S1P-S1PR1 signaling. To investigate how S1P-S1PR1 affects VEGF-A-mediated signaling events, we studied 3 VEGFR-2 phosphorylation and intracellular trafficking following VEGF-A treatment with 4 or without pharmacological S1P pathway modulation. These events, together with recep-5 tor internalization, were described to be critical for growth factor action (Simons et al., 6 2016; Wang et al., 2010) . Similarly, S1PR1 receptor internalization, trafficking to peri-7 nuclear area and persistent signaling from intracellular compartments, were demon-8 strated to be relevant for endothelial barrier regulation (Mullershausen et al., 2009 ). As 9 shown in Fig. 5A , VEGF-A significantly increased VEGFR-2 Tyr1175 phosphorylation that 10 was unaffected by the S1PR1 antagonist NIBR0213 at all tested time points and VEGF-11 A concentrations. This indicates that S1P-S1PR1 is not involved in the initial steps of 12 VEGFR-2 signaling, i.e. receptor dimer formation and autophosphorylation. We next as-13 sessed whether NIBR0213 co-treatment affected VEGFR-2 co-localization with Rab5, an 14 early endosome marker. The co-localization was similar with NIBR0213 co-treatment 15 compared to VEGF-A alone at all tested time points ( Fig S5) . However, further onward 16 VEGFR-2 trafficking to the perinuclear region was significantly reduced by NIBR0213 co-17 treatment compared to VEGF-A alone after 10, 20 and 30 min of treatment (Fig 5B, C) . 18 These data show that S1P-S1PR1 signaling is not required for VEGFR-2 trafficking to the 19 early endosome but for VEGF-A-mediated VEGFR-2 trafficking to the perinuclear region. Studies have demonstrated that S1P-S1PR1 signaling is required for development and 2 homeostasis of blood vessels (Ben Shoham et al., 2012; Gaengel et al., 2012; Jung et 3 al., 2012) . In addition, a signaling cross talk between VEGFR-2 and S1PR1 was reported 4 in blood endothelial cells (Gaengel et al., 2012) . However, in the past different groups 5 have drawn differing conclusions on whether S1P has a pro-or anti-angiogenic role (Ben overall pro-lymphangiogenic effect (Yoon et al., 2008) . While it appeared likely that 10 S1PR1 represents the receptor transducing S1P effects in LECs similar to BECs, there 11 was no clear demonstration of this from earlier studies.
12
This study shows, for the first time, that S1P-S1PR1 activity affects lymphangiogenesis 13 by promoting VEGF-A-dependent LEC proliferation and by limiting LEC migratory and 14 filopodia-forming responses in vivo. Filopodia formation and proliferation are hallmarks of 15 endothelial tip and stalk cells, respectively. These cell phenotypes are key players in vas-16 cular patterning, and thus we suggest that the vascular network morphology is critically 17 dependent on tightly controlled S1P-S1PR1 signaling.
18
While it was previously shown that S1PR1 signaling limits migratory, filopodia-forming Ochsenbein et al., 2016), we conclude that elevated S1P amplifies VEGF-A signaling in 3 addition to ongoing VEGF-C growth factor signals. Therefore, under physiological condi-4 tions, VEGF-C signaling does not saturate LEC proliferation, which can be further en-5 hanced by combined action of VEGF-A and S1P. In support of this, ectopic expression of 6 VEGF-A was shown to increase proliferation rather than migration and filopodia-formation 7 of LECs (Nagy et al., 2002; Wirzenius et al., 2007) . Likewise, neutralization of VEGF-A 8 alone in our developing diaphragm model, in the absence of enhanced S1P signaling, 9 had no effect on assessed morphological parameters. This finding is in line with previ- 
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Inhibition of S1PR1 signaling with the specific antagonist NIBR0213 led to chylus ascites 14 formation and increased filopodia formation as well as branch formation in vivo, demon-15 strating dysfunctional and malformed lymphatic vessels. A similar phenotype was ob-16 tained in animals where S1PR1 was specifically deleted in LECs, emphasizing the im-17 portant LEC-intrinsic signaling role of S1P/S1PR1. Of note, our data are well in line with 18 a previous report showing increased filopodia formation in mice with lymphatic endothelial 19 cell-specific depletion of sphingosine kinase, which is needed for the generation of S1P 20 (Pham et al., 2010) . Furthermore, as increased filopodia-formation is also seen in 21 S1PR1-deficient blood vessels, our data establish a pan-endothelial mechanism.
22
For lymphatics we postulate that S1PR1-mediated inhibition of sprouting acts on alter-1 native growth factor-driven lymphangiogenic processes, independent of VEGF-A. Earlier 2 work showed that VEGF-C is a crucial driver of postnatal lymphangiogenesis (Zarkada et 3 al., 2015; Zhang et al., 2018) and it will be interesting to investigate how S1P and VEGF-4 C signaling converge in vivo in the future.
5
In order to gain better mechanistic insight into how S1P-S1PR1 affects VEGF-A-mediated 6 lymphangiogenic processes we observed in vivo, we characterized S1P-S1PR1 signaling 7 in LECs in vitro. We confirmed that S1P-S1PR1 signals in a constitutive and autocrine 8 fashion, as expected from earlier genetic studies showing that LECs generate S1P in a 9 sphingosine kinase 1/2 -dependent manner in mice (Pham et al., 2010) . Surprisingly, our 10 in vitro data clearly showed that VEGF-A can only signal and exert its mitogenic function 11 when autocrine, constitutive S1P-S1PR1 signaling is active in LECs. The VEGF-A-medi-12 ated proliferative response of LECs was completely inhibited following blockade of 13 S1PR1. In line with this finding, antagonizing S1PR1 also strongly inhibited VEGF-A -14 stimulated ERK1/2 activity. Interestingly, 50% of VEGF-A-induced ERK1/2 activity seems 15 to be S1PR1-independent. However, the proliferation data demonstrate that S1PR1-in-16 dependent ERK1/2 activation is not sufficient to translate into a functional output.
17
A previous report in HUVECs suggested a decrease of VEGF-A-induced pERK1/2 levels 18 with S1P co-treatment (Gaengel et al., 2012) . In our experience, HUVECs responded in 19 a similar way to LECs by increasing the pERK1/2 levels. Taken together, we propose that 20 S1P-S1PR1 signaling is a constitutive, LEC-intrinsic mechanism enhancing VEGF-A sig-21 naling and proliferative function. In line with this conclusion, sphingosine kinases were 22 shown to be important for VEGF-A-mediated ERK1/2 activation in retinal blood endothe-1 lial cells (Maines et al., 2006) and in a bladder tumor cell line (Shu et al., 2002) .
2
Upon VEGF-A stimulation, VEGFR-2 is internalized and traffics through different intracel-3 lular compartments, such as Rab5+ endosomes (Simons et al., 2016) . These steps are 4 important for VEGF-A-mediated downstream signaling and aberrant trafficking of 5 VEGFR-2 was shown to decrease ERK1/2 activation (Lanahan et al., 2010) . As deficient 6 S1PR1 signaling decreased VEGFR-2 trafficking to the perinuclear region, we speculate 7 that S1PR1-mediated VEGFR-2 trafficking is needed for efficient ERK1/2 activation. Fur-8 thermore, as S1PR1 antagonism does not impact VEGFR-2 trafficking to Rab5+ early 9 endosomal compartments, we conclude that the crosstalk between VEGFR-2 and S1PR1 10 signaling happens between early endosomes and compartments in the perinuclear re-11 gion. Interestingly, others have shown that S1PR1 and VEGFR-2 can form signaling com- Interestingly, similar hyperproliferative lymphatic vessel phenotypes as the ones induced 18 by enhanced S1P signaling in our study were described in mice with deficient negative 19 regulators of ERK1/2 signaling, namely SPRED1 and RASA1, as well as for gain-of-func-20 tion of RAF1, a positive regulator of ERK1/2 (Deng et al., 2013; Lapinski et al., 2012; 21 Taniguchi et al., 2007) . Further, lymphatic-specific deletion of the transcription factors 22 FOXC1 and FOXC2 decreased Rasa3 in embryonic LECs, increased S1pr1 levels and 23 activated ERK1/2 that resulted in lymphatic vessel enlargement without changes in 1 branching (Fatima et al., 2016) . Considering these findings together with our finding that 2 S1P-S1PR1 controls VEGF-A-induced ERK1/2 activation, we suggest that S1P acts as 3 an enhancer of the Ras-Raf-MEK-ERK1/2 signaling cascade upon VEGF-A stimulation 4 in vivo, and that negative modulation of S1P-S1PR1 signaling may be beneficial in treat-5 ing certain genetic diseases linked to lymphatic hyperproliferation.
6
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